Skip to content

18 October 2021

Heart disease AI diagnostics med-tech Artrya to list at $105m valuation


Artrya has lodged a prospectus with ASIC with a view to list on the Australian Stock Exchange. This has offered investors an opportunity to buy into a business with a mission to save lives through better detection of heart disease. The funds from the IPO will go towards further research and development, as well as supporting international expansion in 2022. Read more about the commercialisation of our business:

Click here to read the article on Business News Australia